Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Disease area: Airway diseases

Abstract

Introduction Asthma and chronic obstructive pulmonary disease (COPD) display features of overlap in airway physiology and airway inflammation. The relationship between mediator expression and airway inflammation was explored within these airway diseases.
Methods Patients with asthma (54 patients: 21 men) and COPD (49 patients: 36 men) were studied. Clinical characteristics and sputum was collected at entry into the study. A two-step sputum processing method was performed for supernatant and cytospin preparation. The Meso Scale Discovery and Luminex platforms were used to measure cytokines, chemokines and matrix metalloproteinase levels.
Results Analytes sensitive to dithiothreitol (DTT) that had increased recovery in the two step sputum process were IL-1b, 4, 5, 10, 13, IFN-g, TNFRI, GM-CSF, CCL2, 3, 4, 5, 13 and 17. There was a differential expression in IL-8, TNFRI and TNFRII between asthma and COPD (mean fold difference (95% confidence interval) IL-8, 2.6 (1.3 to 5.4), p=0.01; TNFRI, 2.1 (1.3 to 5.4), p=0.03; and TNFRII, 2.6 (1.2 to 5.6), p=0.02). In neutrophilic and eosinophilic airway inflammation, TNFα, TNFRI, TNFRII, IL-6, IL-8 and IL-5 could differentiate between these phenotypes. However, these phenotypes were unrelated to the diagnosis of asthma or COPD.
Conclusion Recovery of sputum mediators sensitive to DTT can be improved using a new sputum processing technique. Within airway inflammatory sub-phenotypes there is a differential pattern of mediator expression that is independent of disease. Whether these inflammatory phenotypes in asthma and COPD confer distinct pathogenesis, therapeutic responses and clinical phenotypes needs to be further evaluated.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Bafadhel, M. McCormick, S. Saha, V. Mistry, S. McKenna, P. Dodson, A. Lloyd, P. Rugman, P. Newbold (Leicester, Loughborough, Sheffield, United Kingdom). Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Eur Respir J 2011; 38: Suppl. 55, 4796

Member's Comments

No comment yet.

Related content which might interest you: Measurements of sputum interleukin-5 in chronic obstructive pulmonary disease patients with eosinophilic airway inflammation Source: Annual Congress 2008 - Phenotyping of asthma and COPD Year: 2008 Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: 325-331 Year: 2002 The role of biomarkers to identify bacterial and eosinophilic airway inflammation in exacerbations of chronic obstructive pulmonary disease Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 Biomarkers in the management of COPD Source: Eur Respir Rev 2009; 18: 96-104 Year: 2009 Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Investigating COPD in longitudinal studies Year: 2013 Multiple inflammatory hits and the pathogenesis of severe airway disease Source: Eur Respir J 2006; 27: 884-888 Year: 2006 Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease Source: Annual Congress 2012 - Asthma and COPD: quality of life and comorbidities Year: 2012 Sputum cytokine profiling according to the type of airway inflammation in obstructive pulmonary diseases Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Association between airway inflammation and systemic inflammation in stable chronic obstructive pulmonary disease Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Suppressed pulmonary expression of leptin in lipopolysaccharide-induced acute and chronic lung inflammation Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS) Year: 2006 Therapeutic responses in asthma and chronic obstructive pulmonary disease Source: Annual Congress 2008 - PG17 - An expert view of the differences between asthma and COPD Year: 2008 Clinical and inflammatory features of exacerbations of occupational chronic obstructive pulmonary disease Source: International Congress 2017 – Shared exposures related to interstitial disease and airflow obstruction Year: 2017 Overlapping biologic exacerbation clusters in asthma and chronic obstructive pulmonary disease have distinct sputum mediator and microbiome profiles Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS) Year: 2018 Systemic inflammation in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: 5S-13S Year: 2003 Bacterial bronchopulmonary infection-induced exacerbation of chronic obstructive pulmonary diseases Source: Eur Respir J 2002; 20: Suppl. 38, 258s Year: 2002 Small airway inflammation in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001 Pattern of airway inflammation and remodeling in mild chronic obstructive pulmonary disease Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 IL-36? – a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease Year: 2021 Peripheral lung remodelling in asthma and chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 893-894 Year: 2004 Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies Source: Eur Respir J 2008; 31: 70-77 Year: 2008